Focus: Renata Medical is a newly founded (2024) medical device company focused on developing stents for infant vascular stenosis, headquartered in Newport Beach, CA. The company operates in the niche pediatric cardiovascular device space with a highly specialized therapeutic focus.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Renata Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Renata Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Off-patent quinazoline diuretic marketed as generic ANDA; presence suggests portfolio acquisition or divestiture integration rather than core pipeline.
Help build intelligence for Renata Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Off-patent beta-1 selective adrenergic blocker marketed as generic ANDA; indicates generic pharmaceutical portfolio rather than core device innovation.
Off-patent antipsychotic marketed as generic ANDA; presence misaligned with stated specialty in pediatric cardiovascular devices.
Off-patent triptan marketed as generic ANDA; therapeutic area (neurology) disconnected from company's cardiovascular device focus.
Off-patent statin marketed as generic ANDA; presence suggests recent acquisition or legacy portfolio asset with no alignment to core device strategy.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo